AI-generated summary
The authors report a split-face, double-blind, randomized trial of 24 women who received one 1064-nm picosecond laser session and then used either a multi-beneficial serum or a placebo on each side of the face for eight weeks. They report greater improvements in photoaging signs and skin barrier measures on the serum side, and no adverse events related to the serum. The study is monocentric and small, so the findings may not generalize.
- Participants
- 24
- Who or what was studied
- Women aged 30 to 48 years with age-associated facial photoaging requesting picosecond laser therapy
- Wavelengths
- 1064 nm
- Limits stated in the abstract
- The abstract describes a small, single-center trial with 24 participants, and the authors do not report a non-treated control group for comparison beyond the placebo side.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
In recent years, skin photoaging has received increasing attention, and laser therapy has become the most commonly used treatment due to its safety and efficacy; emerging evidence suggests that adjunctive "integrated skincare" may enhance treatment benefits by reducing post-procedural reactions and supporting skin barrier repair.
Objective
The split-face, double-blind, randomized, placebo-controlled, monocentric clinical trial was conducted to validate the potential efficacy of anti-photoaging and skin repair of a multifunctional serum formulation following a one-session therapy of 1064-nm picosecond Nd:YAG laser.
Methods
A total of twenty-four participants requesting picosecond laser therapy to address age-associated facial alterations were recruited for the study. Following a two-week washout period, participants underwent a single laser session on Day 1 (T1d) and applied either the multi-beneficial serum or the placebo to the designated facial side twice daily for eight weeks. Their facial skin manifestations were assessed by two dermatologists at baseline, T0, T15d, T29d, and T57d, and the Symptom Score Reduction Index (SSRI) was analyzed later. Non-invasive measurements and self-assessments were also administered at each visit.
Results
Twenty-four women aged 30-48 years completed the trial. The scores for all other manifestations of skin photoaging, with the exception of coarse wrinkles, decreased on both the test and control sides throughout follow-up. Based on SSRI values for individual photoaging signs, clinical efficacy rates for the test sides were superior to their counterparts. Regarding skin barrier function, decreasing transepidermal water loss and increasing stratum corneum hydration were observed on the test side during the period of recovery, with significant intergroup differences on T29d and T57d. Skin tone indicators (erythema index, melanin index, and tone evenness) rose shortly after the laser treatment and then declined on both sides; the magnitudes of reductions were greater on the test sides than on the control ones. Even though the improvement of skin surface evenness was found due to the therapy, the test sides exhibited more favorable changes than the controls, for instance, a reduction in the area proportion of crow's feet. No adverse events related to the test product were found during the study.
Conclusion
The test serum enhanced the efficacy of 1064-nm picosecond laser treatment for facial photoaging and supported skin barrier recovery.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Placebo-controlled, Melanin. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.